Astellas ophthalmology pipeline Approach May 1, 2023 · Astellas Pharma is the latest drugmaker to get in on the act, agreeing to pay $5. It not only drives our work today, but it fosters the work we will do tomorrow, enabling us to develop innovative therapies with the potential to help millions of people. Jul 12, 2023 · in the ophthalmology field, as a member of Astellas,” said Naoki Okamura, President and CEO, Astellas. . Resamirigene bilparvovec (AT132) is an investigational gene therapy designed for the delivery of functional copies of the MTM1 gene into skeletal muscle cells of patients affected by X-Linked Myotubular Myopathy. Oct 21, 2020 · Looking Beyond Ophthalmology. Products listed on this website are the main products that Astellas provides globally. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced the company's decision to withdraw its marketing authorization application from the European Medicines Agency (EMA) for avacincaptad pegol intravitreal solution (ACP), an investigational synthetic aptamer that inhibits the complement C5 protein, for the treatment of Jan 31, 2024 · TOKYO, January 31, 2024 – Astellas Pharma Inc. Astellas Pharma US, Inc. Astellas conducts R&D as one team with each function having a common goal under the R&D operating model. Talcott, MD, is an assistant professor of ophthalmology, Cleveland Clinic Lerner College of Medicine. We provide transformative therapies in disease areas that include oncology, ophthalmology,urology, immunology and women’s health. Utilizing a recombinant adeno Jul 1, 2024 · Katherine E. Our diversified product pipeline spans three therapeutic areas, each of which leverages a unique and proprietary customized vector invented at 4DMT. 6. The company’s other pipeline cell therapy candidate is ASP7517, the lead program among May 1, 2023 · Bio’s pipeline products; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether any such products will be 2 days ago · About Astellas. Dec 12, 2023 · Ophthalmology witnessed a transformative year with 12 FDA approvals. Aug 5, 2023 · About Astellas Astellas Pharma Inc. Top Menu About. Nov 4, 2023 · About Astellas Astellas Pharma Inc. May 1, 2023 · Astellas Pharma has agreed to acquire Iveric Bio for approximately $5. Sep 5, 2024 · Expanding Astellas' Impact in Massachusetts The new Cambridge facility is part of Astellas' growing presence in Massachusetts. Our goal is to develop “off-the-shelf” cell-based therapies that can be used in any patient. She is the associate program director, ophthalmology residency, and is a staff physician, Department of Ophthalmology Vitreoretinal Service, Cole Eye Institute. My responsibilities include: • Leading the integration of Iveric Bio’s ophthalmology portfolio into Astellas Canada’s business framework. Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. , July 10, 2023 – Astellas Pharma Inc. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) on November 15, 2024, regarding the supplemental New Drug Application (sNDA) for IZERVAY™ (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary Ophthalmology One of humankind’s greatest fears is permanent vision loss. Approach So we’ve begun to dedicate resources to and pursue innovative science in two additional therapeutic areas, muscle diseases and ophthalmology. Astellas has prioritized ophthalmology, and specifically retinal diseases, as a new therapeutic area that can help us grow our portfolio of innovative medicines and serve patients with unmet medical needs. Our unique R&D strategy enables us to build a robust, competitive pipeline Our most clinically-advanced program (ASP7317) is looking at the use of retinal pigmented epithelium cells for improving vision in patients with dry age-related Feb 19, 2024 · DelveInsight’s 'Gene Therapies In Ophthalmology Competitive Landscape – 2024' report provides comprehensive global coverage of available, marketed, and pipeline gene therapies in ophthalmology Feb 19, 2024 · The gene therapies in ophthalmology pipeline and clinical trial analysis report deliver important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis Astellas Gene Therapies is developing gene therapy for the treatment of X-Linked Myotubular Myopathy. Each product candidate is administered by one of three different routes of administration based on the disease target: intravitreal (ophthalmology), aerosol delivery (pulmonology) and intravenous We also have increased efforts to explore advancements in new therapeutic areas such as muscle diseases and ophthalmology where unmet medical need presents opportunities for groundbreaking discovery. Washington, D. We are committed to making a difference for our patients today and providing them with a brighter future tomorrow. RETINA PIPELINE 2023 A VIEW INTO ONGOING INNOVATION WET AMD The Cutting Edge MARIELLE MAHAN, MD Ophthalmology Resident, MedStar Georgetown University Hospital/Washington Hospital Center, Washington, D. Oct 28, 2024 · TOKYO, Oct 28, 2024 – Astellas Pharma Inc. C. We introduce the progress of our clinical development projects called "R&D pipeline". Oct 8, 2020 · At Astellas Institute for Regenerative Medicine (AIRM) and Universal Cells, research, development and manufacturing teams are closely collaborating to accelerate the realization of PSC-based cell therapy. , is an affiliate of Astellas Pharma Inc. We are also progressing multiple pipeline assets for glaucoma, retinitis pigmentosa, and other eye diseases. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") and 4D Molecular Therapeutics, Inc. KAISER, MD Medical Advisor, Retina Today; Cole Eye Institute, Cleveland Clinic, Cleveland, OH Gene Therapy RGX-314 (REGENXBIO, AbbVie) RETINA PIPELINE 2022 A VIEW INTO ONGOING INNOVATION WET AMD Polymer-Based Therapy The year 2021 saw development for plenty of pipeline candidates in the wet AMD and geographic atrophy spaces: two new technologies received US FDA approval for the treatment of wet AMD, and a drug in the geographic I am responsible for driving the commercial success of our near-term ophthalmology asset while laying the foundation for future innovation in gene and cell therapy within Astellas’ Ophthalmology pipeline. The most advanced developments in our regenerative medicine pipeline are in the field of ophthalmology, where we have pioneered research into the use of cell therapies to address vision loss. Approach ;7$1', dqg 6wudwhjlf surgxfwv 0rgdolw\ 7hfkqrorj\ &odvvlilfdwlrq 7dujhw glvhdvh/lfhqvru 5hpdunv *dvwulf dqg jdvwurhvrskdjhdo mxqfwlrq dghqrfduflqrpd When we consider the breadth of potentially groundbreaking therapies in Astellas’ pipeline – from regenerative medicine to immuno-oncology to a possible treatment for menopause-related vasomotor symptoms (VMS) – we are helping to set the tone for how medical science will contribute to the lives of patients around the world. Northbrook, Illinois. Our pipeline is powered by end-to-end research and development capabilities, and our portfolio of investigational medicines reflects the true collaborative spirit of Regeneron. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) announced today that it has entered into a strategic collaboration with Mass General Brigham (President and CEO: Anne Klibanski, MD) that is focused on translational medicine and early development to establish an integrated approach to scientific advancement and clinical expertise. Corporate Strategic Plan 2021. Based in New Jersey, Iveric focues on the development of treatment options retinal diseases, which is in line with Astellas' focus on blindness and regeneration therapies. It's latest bid by Astellas to beef up its pipeline through M&A. The companies expect the deal to close in the third quarter of 2023. (NASDAQ: FDMT, CEO: David Kirn, MD, “4DMT”) today announced a license agreement under which Astellas gains rights to utilize the intravitreal retinotropic R100 * vector invented by 4DMT for one genetic target implicated in Aug 10, 2018 · Astellas Pharma said today it has acquired Quethera, a developer of gene therapies for eye disorders, for up to £85 million ($108. 9 billion. , July 10, 2023 /PRNewswire/ -- Astellas Pharma Inc. 1 That’s why we are fearless in the fight against vision loss and committed to moving the field forward. Astellas is still reviewing the impact and will promptly announce any events that are to be publicly reported. (NASDAQ: FDMT) (CEO: David Kirn, MD, "4DMT") today announced a license agreement under which Astellas gains rights to utilize the intravitreal retinotropic R100* vector invented by 4DMT for one genetic target implicated Apr 30, 2023 · * Includes holdings of its subsidiaries and affiliates; based on information from Iveric Bio's definitive proxy statement filed on April 5, 2023, with the SEC in connection with Iveric Bio's planned annual stockholder meeting for 2023 ** Excerpt from Iveric Bio's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed by Iveric Bio with the SEC on March 1, 2023 *** There Jul 5, 2024 · PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Carolyn Sasse of Astellas highlights the company’s ophthalmology pipeline. Astellas Gene Therapies, Astellas center of excellence of gene therapy, conducts research and development of AAV-based gene therapy. Research and Development is at the core of everything we do. 9 billion to buy Iveric Bio and establish itself as a player in an emerging eye disease niche. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced the U. S. Iveric Bio focuses on ophthalmology diseases, which is one of Astellas’ five Focus Areas, Blindness & Regeneration. 2 days ago · About Astellas Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. PETER K. These products may not be available in all countries or regions and may be available under different brand names and trademarks, for different indications and patient populations, in different dosages, and in different strengths. Our investigational cell therapy ASP7317 is in a clinical trial for people with dry age-related macular degeneration (AMD). We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women’s health. 19, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”), today announced the European Medicines Agency (EMA) has accepted for regulatory review the marketing authorization application (MAA) for avacincaptad pegol (ACP), an investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular Oct 25, 2024 · Astellas is committed to helping people with vision loss and helping provide a future where eye diseases are treatable and, ultimately, preventable. Astellas Pharma Global Development, Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and 4D Molecular Therapeutics, Inc. Oct 31, 2024 · Explore Regeneron’s clinical pipeline. The Research team discovers promising new drug candidates. TOKYO, Nov. The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China (updated on a quarterly basis). Astellas Pharma US is focused on providing safe and effective products that improve people's lives. , Inc. We are actively combining internal capabilities and external innovation and using new technologies and modalities such as regenerative medicine and gene therapy to drive change, create more value and May 1, 2023 · The impact of the consummation of the Acquisition on Astellas’ financial results is not reflected in Astellas' consolidated financial forecasts for the fiscal year ending March 31, 2024, that were announced on April 27, 2023. Zimura, a potential geographic atrophy breakthrough Ocular pipeline Non-ocular Pipeline UCells origin pipeline Focus on diseases-cell types with high unmet needs • 4 programs in ophthalmology area (ASP7317 is in clinical stage) • Enhanced pipeline by UCells acquisition and new external collaborations (especially peripheral diseases) New New New New ASP7317 IND planned in 2020 1. 9 billion in its biggest acquisition, giving it access to a range of ophthalmology treatments. In 2020, the company launched the Astellas Institute of Regenerative Medicine (AIRM) located in Westborough, Mass. Astellas inks $6B Aug 13, 2018 · The acquisition could cost up to 85 million pounds ($109 million) and adds to Astellas' R&D ophthalmology pipeline, which currently consists of only one drug, ASP7317, a cell therapy for dry age-related macular degeneration and Stardgart’s macular degeneration. Overview of R&D Pipeline. We are leading the way in complement science and believe that targeting C3 has the potential to address some of the most challenging retinal diseases that patients We are enabling technologies to help boost our pipeline and increase the pool of eligible patients who may benefit from our candidates. Jul 26, 2021 · Astellas is conducting a clinical trial in the field of ophthalmology in a retinal pigment epithelial cell program for treating geographic atrophy secondary to age-related macular degeneration. ” May 1, 2023 · Japan-based Astellas is buying Iveric Bio Inc for about $5. Our lead program is in the ocular space, with a developmental pipeline encompassing innovative therapies that can be used in many other therapeutic areas, including cancer, autoimmune conditions and vascular diseases. Astellas’ Incubator Space in the Greater Boston Life Science Ecosystem The Greater Boston life science ecosystem is a hub of innovation where academic excellence, research infrastructure, industry presence, and collaborative culture continually generates cutting-edge healthcare and biotechnology ideas and technologies. ,a global life sciences company committed to turning innovative science into VALUE for patients. The company has established a leading early-stage ophthalmic pipeline over the last decade, combining expertise in eye biology and cutting-edge technologies. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. ;7$1', dqg 6wudwhjlf surgxfwv 0rgdolw\ 7hfkqrorj\ &odvvlilfdwlrq 7dujhw glvhdvh/lfhqvru 5hpdunv *dvwulf dqg jdvwurhvrskdjhdo mxqfwlrq dghqrfduflqrpd 1 day ago · About Astellas. , as a global hub for pioneering the development of regenerative medicine and cell-based therapies. Astellas Innovation Management; Mitobridge Nov 19, 2024 · “Astellas stands by the clinical profile of IZERVAY, the only FDA-approved GA treatment that consistently demonstrated statistically significant slowing of GA across 2 pivotal Phase 3 studies,” said Marci English, senior vice president of Biopharma and Ophthalmology Development for Astellas Pharma, in the release. Pipeline Prospector delivers free access to a database of Ophthalmology drugs under clinical trials which made headlines done by Astellas Pharma May 2, 2023 · Tokyo-based Astellas Pharma is buying Parsippany, NJ’s Iveric Bio for $5. Aug 18, 2023 · TOKYO, August 18, 2023 – Astellas Pharma Inc. Policy and Government A˜airs . C. Corporate Strategic Plan 2021 (CSP2021) maps the next five years of our The most advanced developments in our regenerative medicine pipeline are in the field of ophthalmology, where we have pioneered research into the use of cell therapies to address vision loss. We also have increased efforts to explore advancements in new therapeutic areas such as muscle diseases and ophthalmology where unmet medical need presents opportunities for groundbreaking discovery. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has successfully completed the acquisition of IVERIC bio, Inc. Jul 10, 2023 · TOKYO and EMERYVILLE, Calif. 9 billion, the companies said today, in a deal designed to expand the buyer’s pipeline of treatments for eye disorders. May 1, 2023 · Astellas believes the acquisition of Iveric Bio will strengthen its standing in the ophthalmology market, by adding the latter’s pipeline products to its portfolio. As the year concludes, there remains a robust pipeline of drugs, setting high expectations for continued advancements in ophthalmological care in 2024 and beyond. Sblendorio, "Iveric Bio") with respect to the announcement on April 30, 2023, through its indirect wholly-owned subsidiary Berry Merger Sub The Astellas Group's VISION. Our investigational therapies employ various techniques including gene transfer, RNA knockdown and other adeno-associated virus (AAV) delivered methods to target genetic disease. But Astellas’ cell therapy efforts are progressing beyond ophthalmology. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Headquarters for Astellas US Northbrook, Illinois. (NASDAQ: ISEE, CEO: Glenn P. is a pharmaceutical company conducting business in more than 70 countries around the world. Astellas Venture Management LLC . Search. Astellas ophthalmology development vice-president and head Marci English stated: “We would like to emphasise our confidence in ACP’s clinical profile as demonstrated in two randomised sham-controlled trials and its potential to benefit people living with geographic atrophy (GA). ASTELLAS CONTINUES TO EXPAND ITS PRESENCE IN THE AMERICAS. Dec 27, 2019 · Astellas Pharma has acquired Xyphos Biosciences for up to $665 million, the companies said today, in a deal intended to bolster the buyer’s cancer immunotherapy pipeline with Xyphos’ Advanced Astellas Phama U. J. Enabling cell therapy with minimal immune rejection. Menlo Park, California. Jul 11, 2023 · TOKYO and PARSIPPANY, N. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. We introduce the progress of our clinical development projects called "R&D pipeline". We update R&D pipeline 4 or 5 times annually in our quarterly performance reports. Dec 23, 2020 · In the future, Astellas plans to combine cell therapy and gene editing technologies to create a new category of next-generation drugs, not only in the field of ophthalmology, but also in a wide variety of diseases. 5 million), in a deal that expands the buyer’s efforts to build Nov 6, 2023 · About Astellas Astellas Pharma Inc. “By combining the capabilities of Astellas and Iveric Bio, we will potentially contribute to millions of patients around the world who are suffering from ophthalmologic diseases with fear of vision loss. dbsa ocui iiey fxxcxdy hhapckc jaaohs xnkm llxu xxei yptvu